{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:13:40Z","timestamp":1759335220469},"reference-count":64,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:p>Psoriasis is a multisystem disease. The cutaneous and musculoskeletal manifestations (psoriatic arthritis) are well recognized. However, the other manifestations of psoriatic disease including metabolic syndrome, atherosclerotic cardiovascular disease, depression, poor self-esteem, and self-destructive habits including obesity, smoking and excess alcohol consumption are underappreciated. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members addressed the need to develop uniform, validated, standardized outcome measures for psoriatic disease, measures that are useful to all stakeholders including patients, physicians, regulators, and payers.<\/jats:p>","DOI":"10.3899\/jrheum.130456","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T11:28:07Z","timestamp":1375356487000},"page":"1428-1433","source":"Crossref","is-referenced-by-count":16,"title":["Psoriasis Outcome Measures: A Report from the GRAPPA 2012 Annual Meeting"],"prefix":"10.3899","volume":"40","author":[{"given":"Alice B.","family":"Gottlieb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"2018112909320988000_40.8.1428.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.03.012"},{"key":"2018112909320988000_40.8.1428.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.042"},{"key":"2018112909320988000_40.8.1428.3","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X15192"},{"key":"2018112909320988000_40.8.1428.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03730.x"},{"key":"2018112909320988000_40.8.1428.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07389.x"},{"key":"2018112909320988000_40.8.1428.6","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"2018112909320988000_40.8.1428.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.012"},{"key":"2018112909320988000_40.8.1428.8","doi-asserted-by":"publisher","DOI":"10.1159\/000083509"},{"key":"2018112909320988000_40.8.1428.9","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.68"},{"key":"2018112909320988000_40.8.1428.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1991.tb04952.x"},{"key":"2018112909320988000_40.8.1428.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"2018112909320988000_40.8.1428.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2011.11.010"},{"key":"2018112909320988000_40.8.1428.13","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"2018112909320988000_40.8.1428.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031237"},{"key":"2018112909320988000_40.8.1428.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.23.3073"},{"key":"2018112909320988000_40.8.1428.16","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-53"},{"key":"2018112909320988000_40.8.1428.17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1468-3083.2006.01651.x","article-title":"Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I\/II study","volume":"20","author":"Schleyer","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2018112909320988000_40.8.1428.18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00017.x"},{"key":"2018112909320988000_40.8.1428.19","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.391"},{"key":"2018112909320988000_40.8.1428.20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D318W9J736","article-title":"A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients","volume":"10","author":"Louden","year":"2004","journal-title":"Dermatol Online J"},{"key":"2018112909320988000_40.8.1428.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06035.x"},{"key":"2018112909320988000_40.8.1428.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08680.x"},{"key":"2018112909320988000_40.8.1428.23","first-page":"260","article-title":"The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician\u2019s Global Assessment (PGA): A comparison","volume":"2","author":"Gottlieb","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"2018112909320988000_40.8.1428.24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03418.x"},{"key":"2018112909320988000_40.8.1428.25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02963.x"},{"key":"2018112909320988000_40.8.1428.26","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890470121019"},{"key":"2018112909320988000_40.8.1428.27","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890470129020"},{"key":"2018112909320988000_40.8.1428.28","doi-asserted-by":"crossref","unstructured":"Bushnell DM Martin ML McCarrier K Gordon K Chiou CF Huang X Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat 2012 Dec 8. [Epub ahead of print]","DOI":"10.3109\/09546634.2012.742950"},{"key":"2018112909320988000_40.8.1428.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06351.x"},{"key":"2018112909320988000_40.8.1428.30","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12329912"},{"key":"2018112909320988000_40.8.1428.31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1346-8138.1999.tb03458.x","article-title":"The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial","volume":"26","author":"Fleischer","year":"1999","journal-title":"J Dermatol"},{"key":"2018112909320988000_40.8.1428.32","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.3.353"},{"key":"2018112909320988000_40.8.1428.33","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890470111018"},{"key":"2018112909320988000_40.8.1428.34","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20543"},{"key":"2018112909320988000_40.8.1428.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100857"},{"key":"2018112909320988000_40.8.1428.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"2018112909320988000_40.8.1428.37","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20577"},{"key":"2018112909320988000_40.8.1428.38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-5945-5-13"},{"key":"2018112909320988000_40.8.1428.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08236.x"},{"key":"2018112909320988000_40.8.1428.40","doi-asserted-by":"publisher","DOI":"10.1159\/000113150"},{"key":"2018112909320988000_40.8.1428.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03682.x"},{"issue":"Suppl 3","key":"2018112909320988000_40.8.1428.42","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/j.1529-8019.2008.00235.x","article-title":"Long-term efficacy of up to 15 months\u2019 efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis","volume":"21","author":"Toth","year":"2008","journal-title":"Dermatol Ther"},{"key":"2018112909320988000_40.8.1428.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"2018112909320988000_40.8.1428.44","doi-asserted-by":"publisher","DOI":"10.1159\/000078581"},{"key":"2018112909320988000_40.8.1428.45","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12365600"},{"key":"2018112909320988000_40.8.1428.46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6846.160"},{"key":"2018112909320988000_40.8.1428.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.11.011"},{"key":"2018112909320988000_40.8.1428.48","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199603000-00003"},{"key":"2018112909320988000_40.8.1428.49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1990.tb04192.x"},{"key":"2018112909320988000_40.8.1428.50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2165\/00019053-199610060-00010","article-title":"The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis","volume":"10","author":"Nichol","year":"1996","journal-title":"Pharmacoeconomics"},{"key":"2018112909320988000_40.8.1428.51","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1169.x"},{"key":"2018112909320988000_40.8.1428.52","doi-asserted-by":"publisher","DOI":"10.1159\/000017503"},{"key":"2018112909320988000_40.8.1428.53","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90189-9"},{"key":"2018112909320988000_40.8.1428.54","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90162-7"},{"key":"2018112909320988000_40.8.1428.55","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.158.2.255"},{"key":"2018112909320988000_40.8.1428.56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2018112909320988000_40.8.1428.57","doi-asserted-by":"publisher","DOI":"10.1207\/s15327752jpa6703_13"},{"key":"2018112909320988000_40.8.1428.58","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004"},{"key":"2018112909320988000_40.8.1428.59","first-page":"374","article-title":"Validation of the Beck Depression Inventory II in HIV-positive patients","volume":"59","author":"Lipps","year":"2010","journal-title":"West Indian Med J"},{"key":"2018112909320988000_40.8.1428.60","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"2018112909320988000_40.8.1428.61","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200101000-00009"},{"key":"2018112909320988000_40.8.1428.62","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00424-3"},{"key":"2018112909320988000_40.8.1428.63","doi-asserted-by":"publisher","DOI":"10.1159\/000069253"},{"key":"2018112909320988000_40.8.1428.64","first-page":"198","article-title":"The OMERACT filter for Outcome Measures in Rheumatology","volume":"25","author":"Boers","year":"1998","journal-title":"J Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.130456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:38:43Z","timestamp":1715809123000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.130456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":64,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,1]]},"published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.3899\/jrheum.130456"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.130456","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}